Beta Bionics (BBNX) EBIT Margin (2024 - 2026)

Beta Bionics (BBNX) posted EBIT Margin of 79.9% for Q2 2026, up 9.06% sequentially from 87.86% in Q1 2026, and up 562.0% YoY from 12.07% in Q2 2025.

Beta Bionics (BBNX) EBIT Margin (2024 - 2026) Analysis & Trends

Beta Bionics has reported EBIT Margin for 3 years, with the latest figure at 79.9% in Q2 2026.

Quarterly EBIT Margin rose 562.0% year-over-year to 79.9% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 69.75% (up 1039.0% YoY) and the FY2025 annual result came in at 71.5%, down 202.0% from the prior year.
EBIT Margin improved to 79.9% in Q2 2026 per BBNX's latest filing, from 87.86% in the prior quarter.
Over five years, EBIT Margin peaked at 50.2% in Q4 2025 and troughed at 105.69% in Q1 2025.
A 3-year average of 75.26% and a median of 75.71% in 2024 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2025 and 2026: EBIT Margin slumped 3259 bps in 2025, then jumped 1783 bps in 2026.
Over 3 years, EBIT Margin stood at 63.78% in 2024, then increased by 21 bps to 50.2% in 2025, then plunged by 59 bps to 79.9% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 79.9%, 87.86%, and 50.2% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	13.44%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	25.18%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	19.10%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	29.48%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	10.30%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	19.15%
10	Beta Bionics	828.10 Mn	647.61 Mn	18.90 Mn	-79.90%

Download Data